



The Impact of Information Technology on Clinical research

Need a n e ?

Topics

The Internet explosion

Clinical Research and
Technology

The Internet explosion

322 Million people use the Internet

2003 estimates are 926 million people

49% are not native English speakers

3 year projections number will rise to
75%

The Internet explosion

WAP – Wireless Application Protocol
Puts internet in hands of non-computer
owners.

Number of mobile subscribers
expected to reach 1.2 billion by 2003

The Internet explosion


175 million web pages of information on the Internet.

12 month period to July 99 over 33 million US adults used Internet to find health and medical information.


Issues facing Pharmaceutical Industry




Reducing R&D Productivity



Reliance on Blockbusters




Decline in Market Growth



IMS Forecasts 1999
PwC Projections 2001

UshZ05/AP44-04c.ppt
ECPI 2000 Pack

Increased Therapeutic Competition



© PricewaterhouseCoopers 2001

Need an e ?



Rank	Corporation	Number of Products in Pipeline			
		1999 R&D \$ Million	Total #	Phase III	Pre- Reg'd
1	Glaxo SmithKline	3,584	269	18	7
2	Pfizer	3,595	245	11	6
3	Merck	2,068	145	5	2
4	Astra Zeneca	2,472	99	3	2
5	BMS	1,663	88	8	6
6	Novartis	1,705	106	14	2
7	Aventis	2,386	191	10	8
8	J&J	1,670	79	7	3
9	AHP	1,464	155	5	7
10	Pharmacia	2,495	164	7	6

* Expected launches 2000 to 2003

Source: IMS Health

Uxb/Z05/AP44-04c.ppt
ECPI 2000 Pack

© PricewaterhouseCoopers 2001

Need an e ?



- Pharmaceutical drugs remain the 6th largest cause of death in the US
- On average, only 40% of individuals benefit from a particular drug
- Drug development costs have risen to over \$600million per drug
- Many medical needs remain unmet
- Regulators struggling with risk versus benefit equation

A new model is needed to produce **safe, efficacious and affordable** drugs

Current Process

Independent

Departmental and Geographic

Very little cross fertilization of
process



From current environment

Established and multi-layered

Reluctant to change

Success judged as control of people or resources

Academic conservatism and science focus

Generally autocratic style of management

Narrow personal development opportunities

Traditional recruitment paths

Some cross functional groups but rarely international

To future environment

Fluid and flat

Change is welcomed

Success judged as delivery of objectives in project environment


Business driven and risk aware


Process/project based organisation, multi-point decision criteria

Multi-career paths encouraged and supported

Recruitment and recognition of new skill types

Cross functional groups from early discovery with international steering/ common interest groups





Need an e ?



	Today's challenges	Tomorrow's opportunities
Computer Aided Trial Design & Simulation	<ul style="list-style-type: none"> • Trial design and simulation • Ongoing trial review 	<ul style="list-style-type: none"> • CDP design and simulation • Ongoing trial review
Integrated Relationship & Trial Management	<ul style="list-style-type: none"> • Internet recruitment • Trial intranets/extranets • CRM, Call centers 	<ul style="list-style-type: none"> • Connected investigator, patient, supplier and pharma community
Electronic Data Capture & Management	<ul style="list-style-type: none"> • EDC/IVRS/WAP/PDAs • Integrated reporting 	<ul style="list-style-type: none"> • Electronic medical records • Remote patient monitoring • Data and workflow integration
On-line Analysis, Reporting & Review	<ul style="list-style-type: none"> • e-Submissions • Rolling review 	<ul style="list-style-type: none"> • Open access ongoing review for Reg Auth's to slice and dice data

Uxb/Z05/AP44-04c.ppt
ECPI 2000 Pack

© PricewaterhouseCoopers 2001

Need an e ?

Technology will *initially*
create as many problems as it
solves

Technology and Process Change
=
Success

Summary

Paper is inefficient

Internet/technology is not going away

Target molecules will increase

Workforce shortage is real

R&D costs must decrease to meet shareholder expectations

Call to action

March to the future

Attempt to minimize FUD factor

Properly analyze the “make versus buy”
decision

Form strategic partnerships

Set proper expectations

If you are not prepared to change process
DO NOTHING

THANK YOU

john.cline@etrial.com